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Introduction
Recurrent or persistent inflammation, featuring familial
Mediterranean fever (FMF), may induce, promote, or
influence susceptibility to carcinogenesis. However, the
association between FMF and malignancy was rarely
described before.
Objectives
To assess the prevalence of malignancy in FMF.
Methods
Demographic data of FMF patients, followed in the
national FMF center at Sheba medical center (n=8352)
and Hadassah Medical Center (n=1083) were obtained
from FMF patient hospital registries. The prevalence of
cancer in the general population, and in the study regis-
tries was attained from the cancer registry of Israel and
analyzed according to age, origin, and cancer type. The
Standardized incidence rates (SIR) of the different cancers
in FMF patients were calculated and compared to the
cancer SIR of the parallel Israeli ethnic population.
Results
Of 9435 FMF patients (4696 men, 4739 female), 363 devel-
oped cancer during the years 1970- 2011. FMF female
patients developed significantly more lymphoma (Hodgkin
and non-Hodgkin) and in-situ cervical cancer than the
matched general population, SIR 2.07 (95% CI 1.12-2.99)
and 1.86 (95% CI 1.20-2.51), respectively. In contrast, male
and female with FMF had a lower gastrointestinal cancer
incidence, SIR 0.68 (95% CI 0.42-0.95) and 0.63 (95% CI
0.36-0.90).
Conclusion
The risk for lymphoma and in-situ cervical cancer is
increased about twice in FMF. Understanding the
underlying mechanism (inflammation? Colchicine?
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